3Q Financial Reports

Merck & Co.

3Q Revenues: $5.4 billion (flat)

3Q Earnings: $940.6 (-34%)

YTD Revenues: $16.6 billion (+2%)

YTD Earnings: $4 billion (+13%)

Comments: Worldwide sales for Singulair were $868 million for the quarter, up 25%. Combined global sales of Zetia and Vytorin, as reported by the Merck/Schering-Plough partnership, exceeded $1 billion for the quarter. Vaccine sales were $555 million, up 64% as a result of the launch of Rotateq, Zostavax and Gardasil, and the strong performance of Proquad. Restructuring costs were $49.6 million for the quarter. The company reserved an additional $598 million in the quarter for future Vioxx legal defense costs.

Schering-Plough

3Q Revenues: $2.6 billion (+13%)

3Q Earnings: $309 million (earnings were $65 million 3Q2005)*

YTD Revenues: $7.9 billion (+11%)

YTD Earnings: $940 million (earnings were $143 million YTD2005)

Comments: Sales increase for the quarter was driven by growth in prescription pharmaceuticals, including higher sales of Remicade, Nasonex and Temodar. Remicade sales were up 34% to $317 million. Nasonex sales were up 30% to $221 million. Temodar sales were up 18% to $179 million. Global cholesterol joint venture sales, which include Vytorin and Zetia, reached more than $1 billion in the quarter.

*3Q2005 results included a charge of $124 million related to an R&D payment for exercising rights to develop and commercialize golimumab.